You are here

Article Text

Article menu

Download PDFPDF

Electronic pages
Correspondence response
Response to: ‘Belimumab and the measurement of fatigue’ by Mazzoni
Free
  1. V Strand1,
  2. R A Levy2,
  3. R Cervera3,
  4. M Petri4
  1. 1Division Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA
  2. 2Department of Medicine, Universidade do Estado do Rio de Janeiro, Brazil
  3. 3Department of Autoimmune Diseases, Hospital Clinic, Barcelona, Spain
  4. 4Department of Rheumatology, Johns Hopkins University, Baltimore, Maryland, USA
  1. Correspondence to Dr Vibeke Strand, Division Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California 94028, USA; vstrand{at}aol.com

https://doi.org/10.1136/annrheumdis-2015-207700

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We agree that fatigue is a common and important symptom of patients with active systemic lupus erythematosus (SLE), and that it is multidimensional, as has been elegantly described in patients with rheumatoid arthritis.1 In fact, randomised controlled trials in SLE have assessed fatigue, as early as the prasterone dehydroepiandrosterone (DHEA) studies (published in 2002–2004) that employed the (Krupp) Fatigue Severity Scale (FSS), developed …

    View Full Text

    Linked Articles